– Ocrevus Zunovo has the potential to expand treatment options to centers without IV infrastructure or with IV constraints, like at a doctor's office –

– This approval is backed by a decade of proven safety and efficacy data of Ocrevus IV, with over 350,000 people treated globally –

– Ocrevus Zunovo offers people with multiple sclerosis (MS) more options to access treatment based on their individual needs –

Genentech, a member of the Roche Group ((SIX: RO, ROG, OTCQX:RHHBY), announced today that the United States Food and Drug Administration (U.S. FDA) has approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC) injection approved for both these forms of multiple sclerosis, giving people living with MS more treatment options.